Table 1 a Fluid reduction and retreatment interval for all eyes and all eyes with fluid greater than 10-nL after successive treatments of faricimab. We see a stable proportion of all eyes near 50% for improvements in total retinal fluid with increases in treatment intervals. In all eyes with fluid greater than 10-nL, we see over 60% of patients demonstrating improvement in total retinal fluid with increases in treatment intervals; b Fluid reduction and retreatment interval for all eyes previously treated with aflibercept after successive treatments of faricimab. We see a stable proportion of eyes above 50% for improvements in total retinal fluid with increases in treatment intervals. In eyes with fluid greater than 10-nL, we see over 57% of patients demonstrating improvement in total retinal fluid with increases in treatment intervals; c Fluid reduction and retreatment interval for all treatment-naive eyes after successive treatments of faricimab. We see a stable proportion of eyes above 80% for improvements in total retinal fluid. In eyes with fluid greater than 10-nL, we see over 85% of patients demonstrating improvement in total retinal fluid.

From: Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study